NEKTAR THERAPEUTICS (NKTR)

↓ Download CSV

CIK 0000906709 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, NEKTAR THERAPEUTICS reported revenue of $55.23M, down 43.9% from the prior year. The company ran a net loss, with a net margin of -297.1%. It held $280.41M in total assets against $190.57M in total liabilities.

Key ratios (FY2025)

-253.7%
Operating margin
-297.1%
Net margin
-182.6%
Return on equity
-43.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$55.23M$98.43M$90.12M$92.06M$101.91M$152.91M$114.62M$1.19B$307.71M$165.44M
Cost of Revenue$0$30.69M$33.77M$21.64M$24.90M$19.48M$21.37M$24.41M$30.55M$30.21M
Operating Income-$140.10M-$105.20M-$263.68M-$376.17M-$446.10M-$425.11M-$440.04M$687.93M-$59.64M-$112.86M
Net Income-$164.08M-$118.96M-$276.06M-$368.20M-$523.84M-$444.44M-$440.67M$681.31M-$96.69M-$153.52M
EPS (Diluted)$-9.73$-8.68$-1.45$-1.97$-2.86$-2.49$-2.52$3.78$-0.62$-1.10
Total Assets$280.41M$303.85M$398.03M$710.60M$1.12B$1.54B$1.98B$2.15B$508.87M$568.87M
Total Liabilities$190.57M$243.11M$267.05M$343.96M$437.68M$461.47M$571.97M$432.60M$421.04M$480.75M
Shareholders' Equity$89.83M$60.74M$130.99M$366.64M$679.51M$1.08B$1.41B$1.72B$87.83M$88.12M
Cash & Equivalents$15.12M$44.25M$35.28M$88.23M$25.22M$198.96M$96.36M$194.91M$4.76M$59.64M
Operating Cash Flow-$208.51M-$175.71M-$192.61M-$304.01M-$412.66M-$313.29M-$328.68M$718.21M-$80.41M-$117.02M
Capital Expenditures$171.0K$1.47M$865.0K$5.68M$14.99M$7.26M$26.29M$14.24M$9.68M$6.39M
Shares Outstanding20.38M12.39M191.38M188.56M185.47M180.09M176.50M173.53M159.52M153.21M